Free Trial
ASX:1AD

AdAlta (1AD) Stock Price, News & Analysis

AdAlta logo

About AdAlta Stock (ASX:1AD)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
135,957 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics by its i-body platform in Australia. Its lead product is AD-214, an antibody therapeutic, which is in Phase I clinical trial for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis and interstitial lung disease, kidney fibrosis, eye fibrosis, and various cancers. AdAlta Limited has collaborative partnerships with GE Healthcare to develop i-body enabled granzyme B PET imaging agents for use in immuno-oncology; and Carina Biotech to develop CAR-T cell products against various solid tumor antigens. The company was incorporated in 2006 and is based in Bundoora, Australia.

Remove Ads
Receive 1AD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AdAlta and its competitors with MarketBeat's FREE daily newsletter.

1AD Stock News Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
See More Headlines

1AD Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that AdAlta investors own include Advanced Micro Devices (AMD), Alibaba Group (BABA), Brookline Capital Acquisition (BCAC), Banxa (BNXAF), Crane (CR), Ford Motor (F) and GS Acquisition Holdings Corp II (GSAH).

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:1AD
CIK
N/A
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.74 million
Price / Cash Flow
1.94
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.63
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (ASX:1AD) was last updated on 3/11/2025 by MarketBeat.com Staff
From Our Partners